Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm (RESTORE SR)

• ClinicalTrials.gov Identifier: NCT02454283
• Recruitment Status: Terminated
• First Posted: May 27, 2015
• Results First Posted: October 17, 2016
• Last Update Posted: October 17, 2016
• Sponsor: Laguna Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Laguna Pharmaceuticals, Inc.

Study Description

Brief Summary:

LGN-VN-003 is a prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation (AF) or atrial flutter (AFL) to normal sinus rhythm. Up to 625 subjects will be randomized in a 2:1 fashion so at least 400 vanoxerine and 200 placebo subjects receive study drug.

Condition or disease	Intervention/treatment	Phase
Atrial Fibrillation or Flutter	Drug: Vanoxerine HCl; Drug: Placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 41 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: RESTORE SR: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Oral Dose of Vanoxerine for The Conversion Of Subjects With REcent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
• Study Start Date: September 2015
• Actual Primary Completion Date: November 2015
• Actual Study Completion Date: November 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Vanoxerine HCl; Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose	Drug: Vanoxerine HCl
Placebo Comparator: Placebo; identically matching placebo capsules, orally, single-dose	Drug: Placebo

Outcome Measures

Primary Outcome Measures :

1. Conversion to Sinus Rhythm [ Time Frame: 24 hours ]
   Conversion to sinus rhythm (or atrial paced rhythm in the case of subjects with a pacemaker and atrial leads) documented by ECG (Holter ECG, 12-lead ECG, monitor lead ECG, or other format ECG) of at least 1 continuous minute within the 24 hours defined by the time of study drug administration through 24 hours after the time of study drug administration.

Secondary Outcome Measures :

1. Length of Stay (From Time of Study Drug Administration) [ Time Frame: 8 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subject has been informed of the investigational nature of this study and has given written informed consent in accordance with institutional, local, and national guidelines.
• Able to return for Day 8 follow up.
• Male or female 18 years of age or greater.
• Onset of AF/AFL within the 7 calendar days preceding randomization, based on symptoms.
• AF/AFL documented by ECG during the screening period.
• Adherence to local clinical standards or the ACC/AHA or ESC practice guidelines for AF/AFL regarding thromboembolic event prevention and treatment.

Exclusion Criteria:

• Previous exposure to vanoxerine HCl.
• Women of childbearing potential (neither surgically sterilized nor post-menopausal defined as cessation of menses for over one year)
• Systolic blood pressure <110 mmHg (unless documented to be usual value).
• Average heart rate <60 bpm documented by screening ECG.
• Average QTc >440 msec documented by screening ECG.
• QRS interval >140 msec documented by screening ECG.
• Paced atrial rhythm on screening ECG.
• History of receiving another Class I or Class III antiarrhythmic drug within 3 days prior to randomization. Excluded Class I antiarrhythmic drugs include quinidine, procainamide, disopyramide, lignocaine, mexilitine, flecainide, and propafenone. Excluded Class III drugs include dofetilide, sotalol, dronedarone, and ranolazine.
• History of amiodarone (oral or IV) within the 90 days prior to randomization.
• Native or prosthetic aortic or mitral stenosis with aortic valve area ≤1.0 cm2 or mitral valve area of <1.5 cm2 or any other valvular diseases for which surgery is indicated.
• Treatment with any loop diuretic (e.g., furosemide, bumetanide, torsemide, ethacrynic acid, etc.) in the 30 days prior to randomization.
• Ejection fraction of <35% within the 3 months prior to randomization (most recent measure if more than one).
• AF/AFL as a result of surgery (postoperative AF/AFL) within 30 days prior to randomization.
• History of electrical cardioversion within the 7 calendar days prior to randomization.
• History of any polymorphic ventricular tachycardia including torsades de pointes.
• History or family history of long QT syndrome or other inherited arrhythmia syndrome.
• History of ventricular tachycardia requiring drug or device therapy.

Contacts and Locations

Locations

United States, Colorado

Littleton, Colorado, United States

United States, District of Columbia

Washington, District of Columbia, United States

United States, Iowa

Iowa City, Iowa, United States

United States, Missouri

Saint Louis, Missouri, United States

Bulgaria

Plovdiv, Bulgaria

Sofia, Bulgaria

Hungary

Budapest, Hungary

Hodmezovasarhely, Hungary

Pecs, Hungary

Rokus, Hungary

Zalaegerszeg, Hungary

Israel

Ashkelon, Israel

Safed, Israel

Russian Federation

Moscow, Russian Federation

Saint Petersburg, Russian Federation

Vladimir, Russian Federation

Sponsors and Collaborators

Laguna Pharmaceuticals, Inc.

More Information

• Responsible Party: Laguna Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT02454283
• Other Study ID Numbers: LGN-VN-003
• First Posted: May 27, 2015
• Results First Posted: October 17, 2016
• Last Update Posted: October 17, 2016
• Last Verified: June 2016

Additional relevant MeSH terms:

Atrial Fibrillation; Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Vanoxerine; Dopamine Uptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Dopamine Agents; Neurotransmitter Agents; Physiological Effects of Drugs